Immunogenicity and safety of intradermal influenza vaccine in children

Esposito, Susanna; Daleno, Cristina; Picciolli, Irene; Tagliaferri, L.; Scala, Alessia; Prunotto, Giulia; Montinaro, Valentina; Galeone, Carlotta; Principi, Nicola

doi:10.1016/j.vaccine.2011.08.021

Cited by 20 publications

(25 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reactogenicity was typically mild or moderate in severity and short-lived with the majority of symptoms resolving within 3 d. An increase in local reactions is to be expected with injections close to the skin surface, as opposed to deep muscle intramuscular injections, and as reported in previous studies. [24][25][26][27][28][29] Despite the higher incidence of injection site reactions, the high satisfaction with intradermal injection system emerged from several studies in young adults and in older people and the good acceptability profile of intradermal vaccine reflects the high willingness to get re-vaccinated in the following season. 16,17,25,30 The present study demonstrated that the immunogenicity of Intanza ® 15 μg intradermal vaccine was superior than that of Inflexal ® V virosomal influenza vaccine, when the immune response was evaluated against circulating strains.…”

Section: Discussionmentioning

confidence: 99%

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60

Ansaldi

Orsi

Florentiis

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60

Ansaldi

Orsi

Florentiis

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…33 Furthermore, an ID quadrivalent inactivated influenza vaccine was found to be noninferior to an ID trivalent inactivated influenza vaccine. 30 For children, overall, ID vaccination was favorable to IM [34][35][36] or SC 37 injection with respect to immunogenicity and/or dose sparing, although subject age and antigen dose differed among the studies. Two studies showed comparable efficacy for ID vaccination, with a dose reduction of 80% 34 or 60%.…”

Section: Efficacy and Safety Of Id Vaccines In Infants And Childrenmentioning

confidence: 97%

Intradermal vaccination for infants and children

Saitoh

Aizawa

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Intradermal (ID) vaccination induces a more potent immune response and requires lower vaccine doses as compared with standard vaccination routes. To deliver ID vaccines effectively and consistently, an ID delivery device has been developed and is commercially available for adults. The clinical application of ID vaccines for infants and children is much anticipated because children receive several vaccines, on multiple occasions, during infancy and childhood. However, experience with ID vaccines is limited and present evidence is sparse and inconsistent. ID delivery devices are not currently available for infants and children, but recent studies have examined skin thickness in this population and reported that it did not differ in proportion to body size in infants, children, and adults. These results are helpful in developing new ID devices and for preparing new vaccines in infants and children.

show abstract

“…Local adverse events were more common in subjects with intradermal vaccination, but they were mild and transient. Systemic adverse events were rare, and their frequency did not differ between groups [15].…”

Section: Introductionmentioning

confidence: 87%

“…Finally, skin administration of IIV with a microinjection system was found effective in children aged ‡3 years [15]. Compared with virosomal-adjuvanted intramuscular IIV, intradermal IIV resulted in similar seroconversion and seroprotection rates and geometric mean antibody titers for A/H1N1 and A/H3N2 antigens, but it was significantly more immunogenic against the B strain, for which the immune response is usually the weakest.…”

Section: Introductionmentioning

confidence: 99%